- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05782777
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
Study Overview
Status
Conditions
Detailed Description
All eligible patients who underwent coronary revascularization with newer generation DES implantation will be enrolled according to inclusion/exclusion criteria after voluntary agreement with informed consent. At the time of enrollment, the investigators will stratify the patients according to LDL-cholesterol <100mg/dL, acute coronary syndrome, and DES type, and randomly assign them in two groups according to lipid-lowering therapy with a 1:1 ratio: "Combination therapy group" vs. "Statin monotherapy group". In this study, four types of new generation DES will be used: Orsiro (Biotronik), Firehawk (Microport), Genoss (Genoss) or D+Storm (CGBIO).
In this study, OCT substudy will be performed for the patients with diffuse long lesions requiring total stented length ≥40 mm (targeted for 1000 patients in the trial). Corresponding patients will be randomly assigned into two groups according to the OCT-based optimal expansion criteria with a 1:1 ratio: meeting "Absolute expansion" vs. "Relative expansion". Absolute expansion criteria indicate minimum stent area (MSA) >4.5mm2 and relative expansion criteria indicate MSA > 80% of average reference lumen area. The patients will receive DES implantation under OCT guidance and stent optimization will be performed to satisfy each expansion criteria.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Byeong-Keuk Kim
- Phone Number: 82-2228-8460
- Email: kimbk@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Yonsei University Health system, Severance Hospital
-
Contact:
- Byeong-Keuk Kim
- Phone Number: 82-2228-8460
- Email: kimbk@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 19-85 years
- Patients who underwent coronary revascularization with newer generation DES implantation
Exclusion Criteria:
- Allergy or hypersensitive to ezetimibe or statin
- Active liver disease or persistent unexplained serum AST/ALT elevation more than 2 times the upper limit of normal range
- History of any adverse drug reaction requiring discontinuation of statin
- Pregnant women, women with potential childbearing, or lactating women
- Life expectancy less than 3 years
- Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
- Inability to understand or read the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination therapy group
Ezetimibe/high-intensity statin combination therapy
|
The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg.
During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
|
Active Comparator: Statin monotherapy group
High-intensity statin monotherapy
|
The initial dose of lipid-lowering therapy will be atoravastatin 40mg.
During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy of lipid lowering therapy
Time Frame: Within 3 years after the enrollment
|
Composite of all-cause death, myocardial infarction (MI), any coronary revascularization, hospitalization for unstable angina, or nonfatal stroke within 3 years
|
Within 3 years after the enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects achieving target LDL-cholesterol <55 mg/dL or 70 mg/dL at 6 weeks, 1, 2, and, 3 years
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Rate of cross-over into the non-allocated therapy
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Each component of primary endpoint A. All-cause death (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Each component of primary endpoint B. MI (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Each component of primary endpoint C. Any coronary revascularization (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Each component of primary endpoint D. Hospitalization for unstable angina (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Each component of primary endpoint E. Nonfatal-stroke (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Cardiac death (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Stent thrombosis (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Target-vessel revascularization (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Target-lesion revascularization (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
BARC type 2-5 bleeding (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
BARC type 3-5 bleeding (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Patient-oriented composite endpoint which is composite of all-cause death, MI, or any coronary revascularization (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Device-oriented composite endpoint which is composite of cardiovascular death, MI, or clinically-driven target-vessel revascularization (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Difference in antiplatelet therapy strategy (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Difference in high-ischemic risks (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
Difference in high-bleeding risks (percentage)
Time Frame: Within 3 years after the enrollment
|
Within 3 years after the enrollment
|
|
different OCT optimization criteria when treating very long lesions
Time Frame: Within 3 years after the enrollment
|
A. Primary endpoint (percentage) B. Stent thrombosis (percentage) C. Target-vessel revascularization (percentage) D. Target-lesion revascularization (percentage) E. Patient-oriented composite endpoint (percentage) F. Device-oriented composite endpoint ((percentage)
|
Within 3 years after the enrollment
|
Safety endpoint related to lipid-lowering medication
Time Frame: Within 3 years after the enrollment
|
A. New-onset DM, worsening of glycemic control or HOMA-index (percentage) B. Occurrence of SAMS requiring change of therapy regimen or dosage (percentage) C. Elevation of muscle enzymes which is creatine kinase > 4 x Upper Normal Limit (percentage) D. Elevation of hepatic enzymes which is aminotransferase > 3 x Upper Normal Limit (percentage) E. Elevation of serum creatinine level which is > 50% from baseline (percentage) F. Increase of proteinuria (percentage) G. Diagnosis of cancer (percentage)
|
Within 3 years after the enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Byeong-Keuk Kim, Severance Cardiovascular Hospital, Yonsei University Health System
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Ezetimibe
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
Other Study ID Numbers
- 4-2022-1335
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
-
Sección Hemodinamica y Cardiologia IntervencionistaUnknownCoronary Artery Lesions With Implantation of Coronary DeviceSpain
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
China National Center for Cardiovascular DiseasesPeking University International Hospital; Beijing Shijitan Hospital, Capital... and other collaboratorsNot yet recruitingMultivessel Coronary Artery Disease | Coronary Artery Bypass Grafting | Complete Revascularization
-
US Department of Veterans AffairsUniversity of UtahWithdrawnCoronary Arteriosclerosis | Coronary Artery Bypass Graft | Myocardial RevascularizationUnited States
-
Yonsei UniversityActive, not recruiting
-
Institute for Atherosclerosis Research, RussiaRecruitingMyocardial Ischemia | Coronary Arteriosclerosis | Coronary Artery Bypass Grafting | Percutaneous Coronary RevascularizationRussian Federation
-
Ministry of Science and Higher Education, PolandCompletedMyocardial Ischemia | Coronary Artery Stenosis | Myocardial RevascularizationUnited States, Poland
-
University of UlmCompletedQuality of Life | Stable Coronary Artery Disease | Coronary Angiography | Myocardial Revascularization | Cardiac Magnetic Resonance Imaging | Outcomes and PrognosisGermany
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
University of ÉvoraCompletedPatients With Coronary Artery DiseasePortugal
Clinical Trials on ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
-
Samsung Medical CenterNot yet recruitingMetabolic Syndrome | Dyslipidemias | Coronary Artery Calcification
-
Seung-Whan Lee, M.D., Ph.D.Yuhan CorporationRecruitingPre Diabetes | ASCVDKorea, Republic of
-
Seoul National University Bundang HospitalYuhan CorporationCompletedCardiovascular DiseasesKorea, Republic of
-
Yonsei UniversityRecruitingAtherosclerotic Cardiovascular DiseaseKorea, Republic of
-
AkrikhinRussian National Atherosclerosis SocietyCompletedCardiovascular Diseases | Lipid Metabolism DisordersRussian Federation
-
Federal University of São PauloCompletedInflammation | Hypercholesterolemia | Cardiovascular Risk | PrediabetesBrazil
-
Yonsei UniversityNot yet recruitingPeripheral Artery Disease | Polyvascular DiseaseKorea, Republic of